Literature DB >> 12209712

Provider case volume and outcome in the evaluation and treatment of patients with mammogram-detected breast carcinoma.

Mark D McKee1, Michael D Cropp, Andrew Hyland, Nancy Watroba, Brian McKinley, Stephen B Edge.   

Abstract

BACKGROUND: Practice volume may affect the outcome of patients with breast carcinoma. Defining factors that influence the relation of volume and outcome for the diagnosis and treatment of breast carcinoma is important, because breast carcinoma is common, and care is decentralized.
METHODS: Community-wide diagnosis and treatment of mammogram-detected breast carcinoma was examined using claims data from a single insurer representing 25% of the regional population. Among 1001 mammogram-directed breast biopsies, the rate of breast carcinoma diagnosed by stereotactic core needle biopsy (SCNB) or excisional biopsy with needle localization (EBNL) and the rate at which breast-conserving surgery (BCS) was used were analyzed. Outcome and practice volume were examined for surgeons, radiologists, and medical centers.
RESULTS: Two hundred twenty-four tumors were diagnosed by EBNL (604 diagnoses) and SCNB (397 tumors), for a 22.4% positive biopsy rate. The median number of procedures per physician was one. Positive biopsy rates for radiologists, surgeons, and medical centers did not correlate with practice volume. Positive biopsy rates for high-volume physician providers and medical centers ranged from 9% to 46%. The BCS rate was 45% and 64% for surgeons treating one or more than one claim, respectively. Tumor stage and surgeon case volume were the only independent predictors of BCS (P < 0.05).
CONCLUSIONS: There is wide variation in diagnosis and treatment outcomes for patients with mammogram-detected breast carcinoma. Overall, practice volume was correlated with the use of BCS but not with the rate of positive biopsy. A wide variation in the positive biopsy rate among high-volume providers and medical centers suggests that volume of practice is not a surrogate for quality in the diagnosis of breast carcinoma. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10737

Entities:  

Mesh:

Year:  2002        PMID: 12209712     DOI: 10.1002/cncr.10737

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Total thyroidectomy (TT) for management of benign thyroid disease.

Authors:  Oscar Jameson Stokes
Journal:  World J Surg       Date:  2004-01-20       Impact factor: 3.352

2.  Accuracy of screening mammography interpretation by characteristics of radiologists.

Authors:  William E Barlow; Chen Chi; Patricia A Carney; Stephen H Taplin; Carl D'Orsi; Gary Cutter; R Edward Hendrick; Joann G Elmore
Journal:  J Natl Cancer Inst       Date:  2004-12-15       Impact factor: 13.506

Review 3.  Shaping the future of surgery: the role of private regulation in determining quality standards.

Authors:  Rachael A Callcut; Tara M Breslin
Journal:  Ann Surg       Date:  2006-03       Impact factor: 12.969

4.  Re-examining the significance of surgical volume to breast cancer survival and recurrence versus process quality of care in Taiwan.

Authors:  Raymond N Kuo; Kuo-Piao Chung; Mei-Shu Lai
Journal:  Health Serv Res       Date:  2012-06-07       Impact factor: 3.402

5.  Racial/ethnic disparities in knowledge about risks and benefits of breast cancer treatment: does it matter where you go?

Authors:  Sarah T Hawley; Angela Fagerlin; Nancy K Janz; Steven J Katz
Journal:  Health Serv Res       Date:  2008-04-01       Impact factor: 3.402

Review 6.  Multidisciplinary breast centres in Germany: a review and update of quality assurance through benchmarking and certification.

Authors:  Markus Wallwiener; Sara Y Brucker; Diethelm Wallwiener
Journal:  Arch Gynecol Obstet       Date:  2012-06       Impact factor: 2.344

7.  Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care.

Authors:  Sara Y Brucker; Michael Bamberg; Walter Jonat; Matthias W Beckmann; Andreas Kämmerle; Rolf Kreienberg; Diethelm Wallwiener
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.